From Polymer Chemistry and Physicochemistry to Nanoparticulate Drug Carrier Design and Applications

Tissue Engineering and Novel Delivery Systems

Volumn , Issue , 2003, Pages 563-598

  Vauthier, C ^a   Fattal, E ^a   Labarre, D ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85180860669     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203913338-26     Document Type: Chapter

References (231)

1. Oku N, Tokudome Y, Asai T, Tsukada H. Evaluation of drug targeting strategies and liposomal trafficking. Curr. Pharm. Design 2000; 6:1669-1691.
2. Gabizon AA. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin. Cancer Res 2001; 7:223-225.
3. Bendas G. Immunoliposomes: a promizing approach to targeting cancer therapy. Biodrugs 2001; 15:215-224.
4. De Jaeghere F, Doelker E, Gurny R. Nanoparticles. In: Mathiowitz E, ed. The Encyclopedia of Controlled Drug Delivery. New York: J. Wiley and Sons, 1999:641-664.
5. Vauthier C, Couvreur P. Development of polysaccharide nanoparticles as novel drug carrier systems. In: Wise DL, ed. Handbook of Pharmaceutical Controlled Release Technology. New York: Marcel Dekker, 2000:413-429.
6. Kumar NMVR. Nano and microparticles as controlled drug delivery devices. J. Pharm. Pharmaceut. Sci 2000; 3:234-258.
7. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Rel 2001; 70:1-20.
8. Fattal E, Vauthier C. Nanoparticles as drug delivery systems. In: Swarbrick J, Boylan JC, eds. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker, 2002:1874-1892.
9. Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule technology: a review. Crit. Rev. Drug Del. Systems 2002; 19:99-134.
10. Vauthier C, Couvreur P. Biodegradation of poly(alkylcyanoacrylates). In: Matsumara JP, Steinbuchel A, eds. Handbook of Biopolymers. Miscellanous Biopolymers and Biodegradation of Synthetic Polymers. Vol. Vol 9. New York: Wiley-VHC, 2002.
11. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug. Deliv. Rev 2002; 54:631-651.
12. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Del. Rev 2001; 47:113-131.
13. Rosier A, Vandermeulen GWM, Klok HA. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv. Drug Del. Rev 2001; 53:95-108.
14. Couvreur P, Grislain L, Lenaerts V, Brasseur F, Guiot P, Biornacki A, Biodegradable polymeric nanoparticles as drug carrier for antitumor agents. In; Guiot P, Couvreur P, eds. Polymeric Nanoparticles and Microparticles. FL: Boca Raton, 1986:27-93.
15. Florence AT, Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv. Drug Del. Rev 2001; 50:S69-S89.
16. Kreuter J. Nanoparticles. In: Kreuter J, ed. Colloidal Drug Delivery Systems. New-York: Marcel Dekker, 1994:219-342.
17. Kawashima Y. Nanoparticulate systems for improved drug delivery. Adv. Drug Del. Rev 2001; 47: 1-2.
18. Birrenbach G, Speiser P. Polymerized micelles and their use as adjuvants in immunology. J. Pharm. Sci 1976; 65:1763-1766.
19. Vauthier C, Seiller M, Weingarten C, Couvreur P. Contribution to the development of oral dosage form for insulin delivery. STP Pharma Sciences 1999; 9:391-396.
20. Gref R, Minamitake Y, Peracchia M-T, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263:1600-1603.
21. Landfester K. Polyreactions in miniemulsions. Macromol. Rapid. Commun 2001; 22:896-936.
22. Lowell PA, El-Aasser MS. Emulsion polymerization and emulsion polymers. In: Lowell PA, El-Aasser MS, eds. New York: Wiley, 1997:801.
23. Couvreur P, Kante B, Roland M, Guiot P, Baudhuin P, Speiser P. Poly(cyanoacrylate) nanoparticles as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J. Pharm. Pharmacol 1979; 31:331-332.
24. Choi YK, Bae YH, Kim SW. Block copolymer nanoparticles of ethylene oxide and isobutylcyanoacrylate. Macromolecules 1995; 28:8419-8421.
25. Bazile D, Prud'homme C, Bassoulet M-T, Marlard M, Spenlehauer G, Veillard M. Stealth Me-PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci 1995; 84:493-498.
26. Peracchia MT, Desmaele D, Couvreur P, D'Angelo J. Synthesis of a novel poly(PEG-cyanoacrylateco-alkylcyanoacrylate) amphiphilic copolymer for the development of "stealth" PEG-coated nanoparticles. Macromolecules 1997; 30:846-851.
27. Vauthier-Holtzscherer C, Benabbou S, Spenlehauer G, Veillard M, Couvreur P. Methodology for the preparation of ultradispersed polymer systems. STP Pharma Sci 1991; 1:109-116.
28. Odian G. Principles of Polymerization. 3rd Ed.. New York: J. Wiley and Sons, 1991.
29. Pichot C, Delair T. Functional nanospheres by emulsion polymerization. In: Arshady R, ed. Micro-spheres, Microcapsules and Liposomes. London: Citus Book, 1999:125-164.
30. Charles M-H, Charreyre M-T, Delair T, Elaissari A, Pichot C. Oligonucleotides-polymer nanoparticle conjugates: diagnostic applications. STP Pharma Sci 2001; 11:251-263.
31. Kreuter J, Speiser P. New adjuvants on a poly(methylmethacrylate) base. Infec. Immunol 1976; 13: 204-210.
32. Costa G, Cronin JP, Pepper DC, Loonan C. Termination and transfer by acids in the pyridine-initiated polymerization of butyl cyanoacrylate. Eur. Polym. J 1983; 19:939-945.
33. Douglas SJ, Ilium L, Davis SS. Particle size and size distribution of poly(butyl 2-cyanoacrylate) nanoparticles. II. Influence of stabilizers. J. Colloid Interface Sci 1985; 103:154-163.
34. Nehan N, Birkinshaw C. Clarke. Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerization and particle formation. Biomaterials 2001; 22(11): 1335—1344.
35. Peracchia MT, Vauthier C, Puisieux F, Couvreur P. Development of sterically stabilized poly(isobutyl 2-cyanoacrylate) nanoparticles by chemical coupling of poly(ethylene glycol). J. Biomed. Mater. Res 1997; 34:317-326.
36. Peracchia MT, Vauthier C, Popa M, Puisieux F, Couvreur P. Investigation on the formation of sterically stabilized poly(ethylene glycol/isobutylcyanoacrylate) nanoparticles by chemical grafting of poly(ethylene glycol) during polymerization of isobutylcyanoacrylate. STP Pharma Sci 1997; 7: 513-520.
37. Vansnick L, Couvreur P, Christiaens-Ley D, Roland M. Molecular weights of free and drug-loaded nanoparticles. Pharm. Res 1985; 1:36-41.
38. Gallardo MM, Roblot-Treupel L, Mahuteau J, Genin I, Couvreur P, Plat M, Puisieux F. Nanocapsules et nanospheres d'alkylcyanoacrylate. Interaction principe actif-polymere. Proceedings of the 5th International Congress of Pharmaceutical Technology, APGI, Paris, France, 1989.
39. Guize V, Drouin J Y, Benoit J, Mahuteau J, Dumont P, Couvreur P. Vidarabine-loaded nanoparticles: a physicochemical study. Pharm. Res 1990; 7:736-741.
40. Grangier JL, Puygrenier M, Gautier JC, Couvreur P. Nanoparticles as carriers for growth hormone releasing factor. J. Control. Rel 1991; 15:3-13.
41. Seijo B, Fattal E, Roblot-Treupel L, Couvreur P. Design of nanoparticles of less than 50 nm in diameter. Preparation, characteriation and drug loading. Int. J. Pharm 1990; 62:1-7.
42. Alonso MJ, Sanchez A, Torres D, Seijo B, Vila-Jato JL. Joint effect of monomer and stabilizer concentrations on the physico-chemical characteristics of poly(butyl-2-cyanoacrylate) nanoparticles. J. Microencapsulation 1990; 7:517-526.
43. Lenaerts V, Raymond P, Juhasz J, Simard MA, Jolicoeur C. New method for the preparation of cyanoacrylic nanoparticles with improved colloidal properties. J. Pharm. Sci 1989; 78:1051-1052.
44. Lescure F, Zimmer C, Roy D, Couvreur P. Optimization of polycyanoacrylate nanoparticle preparation: influence of sulfur dioxide and pH on nanoparticle characteristics. J. Coll. Interface Sci 1992; 154:77-86.
45. Verdun C, Couvreur P, Vranckx H, Lenaerts V, Roland M. Development of a nanoparticle controlled release formulation for human use. J. Control. Rel 1986; 3:205-210.
46. Sommerfeld P, Schroeder U, Sabel BA. Long-term stability of PBCA nanoparticles suspensions suggests clinical usefulness. Int. J. Pharm 1997; 155:201-207.
47. Sommerfeld P, Sabel BA, Schroeder U. Sterilization of unloaded polybutylcyanoarylate nanoparticles. Int. J. Pharm 1998; 164:113-118.
48. Monza da Silveira A, Ponchel G, Puisieux F, Duchene D. Combined poly(isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs. Pharm. Res 1998; 15:1051-1055.
49. Duchene D, Wouessidjewe D, Ponchel G. Cyclodextrins and carrier systems. J. Control. Rel 1999; 62:263-268.
50. Boudad H, Legrand P, Lebas G, Cheron M, Duchene D, Ponchel G. Combined hydroxypropylbeta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int. J. Pharm 2001; 218:113-124.
51. Labib A, Lenaerts V, Chouinard F, Leroux JC, Ouellet R, Lier JE. Biodegradable nanospheres containing phthalocyanines and naphthalocyanines for targeted photodynamic tumor therapy. Pharm. Res 1991; 8:1027-1031.
52. Ghanem GE, Joubran C, Arnould R, Lejeune F, Fruhling J. Labelled polycyanoacrylate nanoparticles for human in vivo use. Appl. Radiat. Isot 1993; 44:1219-1224.
53. Douglas SJ, Ilium L, Davis SS. Poly(butyl-2-cyanoacrylate) nanoparticles with differing surface charges. J. Control Rel 1986; 3:15-23.
54. Yang SC, Ge HX, Jiang XQ, Yang CZ. Formation of positively charged poly(butyl cyanoacrylate) nanoparticles stabilized with chitosan. Colloid Polym. Sci 2000; 278:285-292.
55. Al Khoury-Fallouh N, Roblot-Treupel L, Fessi H, Devissaguet JP, Puisieux F. Development of a new process for the manufacture of poly(isobutylcyanoacrylate) nanocapsules. Int. J. Pharm 1986; 28:125-136.
56. Chouinard F, Kan FWF, Leroux JC, Foucher C, Lenaerts V. Preparation and purification of polyisohexylcyanoacrylate nanocapsules. Int. J. Pharm 1991; 71:211-217.
57. Fresta M, Cavallaro G, Giammona G, Wehrli E, Puglisi G. Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. Biomaterials 1996; 17: 751-758.
58. Gallardo MM, Couarraze G, Denizot B, Treupel L, Couvreur P, Puisieux F. Preparation and purification of isohexylcyanoacrylate nanocapsules. Int. J. Pharm 1993; 100:55-64.
59. Aboubakar M, Puisieux F, Couvreur P, Deyme M, Vauthier C. Study of the mechanism of insulin encapsulation in poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization. J.Biomed. Mater. Res 1999; 47:568-576.
60. Wohlgemuth M, Machtle W, Mayer C. Improved preparation and physical studes of polybutylcyanoacrylate nanocapsules. J. Microencapsulation 2000; 17:437-448.
61. Puglisi G, Fresta M, Giammona G, Venture CA. Influence of the preparation conditions in poly(ethylcyanoacrylate) nanocapsules formation. Int. J. Pharm 1995; 125:283-287.
62. Damge C, Michel C, Aprahamiam M, Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 1988; 37:246-251.
63. Damge C, Vonderscher J, Marbach P, Pinget M. Poly(alkyl cyanoacrylate) nanocapsules as a delivery system in the rat for octreotide, a long-acting somatostatin analogue. J. Pharm. Pharmacol 1997; 49:949-954.
64. Gasco M, Trotta M. Nanoparticles from microemulsions. Int. J. Pharm 1986; 29:267-268.
65. Vranckx H, Demoustier M, Deleers M. A new nanocapsule formulation with hydrophilic core: application to the oral administration of salmon calcitonin in rats. Aur. J. Pharm. Pharmacol 1996; 42:345-347.
66. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm. Res 2000; 17:707-714.
67. Watnasirichaikul S, Davies NM, Rades R, Tucker IG. Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions. Pharm. Res 2000; 17:684-689.
68. De Keyser JL, Poupaert JH, Dumont P. Poly(diethyl methylidenemalonate) nanoparticles as a potential drug carrier: preparation, distribution and elimination after intravenous and peroral administration to mice. J. Pharm. Sci 1991; 80:67-70.
69. Breton P, Guillon X, Roy D, Lescure F, Riess G, Bru N, Roques-Carmes C. Physico-chemical characterization, preparation and performance of poly(methylidene malonate 2.1.2) nanoparticles, Biomaterials 1998; 19:271-281.
70. Lescure F, Seguin C, Breton P, Bourrinet P, Roy D, Couvreur P. Preparation and characterization of novel poly(methylidene malonate 2.1.2.)-made nanoparticles. Pharm. Res 1994; 11:1270-1277.
71. Roy D, Guillon X, Lescure F, Couvreur P, Bru N, Breton P. On shelf stability of freeze-dried polyCmethylidene malonate 2.1.2) nanoparticles. Int. J. Pharm 1997; 148:165-175.
72. Desire L, Mysiakine E, Bonnafous D, Sogodira S, Breton P, Bru-Magniez N, Couvreur P. Delivery of cell communication factors with VL4001, a (methylidene malonate)-based composition. Proceedings of the 29th Annual Meeting of the Controlled Release Society, Seoul, Korea, 2002.
73. Kissel T, Li Y, Unger F. ABA-triblock copolymers from biodegradable polyester A-blocks and hydrophilic poly(ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins. Adv. Drug Del. Rev 2002; 54:99-134.
74. Peracchia MT, Desmaele D, Vauthier C, Labarre D, Fattal E, D'Angelo J, Couvreur P. Development of novel technologies for the synthesis of biodegradable pegylated nanoparticles. In: Gregoriadis B, McCormack B, eds. Targeting of Drugs. Strategies for Stealth Therapeutic Systems. Vol. 6. New York: Plenum Press, 1998:225-239.
75. Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, Gomis JM, Appel M, d'Angelo J, Couvreur P. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control. Rel 1999; 60:121-128.
76. Jung T, Breitenbach A, Kissel T. Sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide)s facilitate the preparation of small negatively charged biodegradable nanospheres. J. Control. Rel 2000; 67:157-169.
77. Yang L, Alexandridis P. Physicochemical aspects of drug delivery and release from polymer-based colloids. Curr Opin Coll. Interface Sci 2000; 5:132-143.
78. Kabanov AV, Lemieux P, Vinogradov S, Alakhov V. Pluronic® block copolymers: novel functional molecules for gene therapy. Adv. Drug Del. Rev 2002; 54:223-233.
79. Passirani C, Ferrarini L, Barratt G, Devissaguet J-P, Labarre D. Preparation and characterization of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). J. Biomat. Sci. Polym Ed 1999; 10:47-62.
80. Passirani C, Barratt G, Devissaguet J-P, Labarre D. Interactions of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) with the complement system. Life Sciences 1998a; 62:775-785.
81. Passirani C, Barratt G, Devissaguet J-P, Labarre D. Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly (methyl methacrylate). Pharm. Res 1998b; 15:1046-1050.
82. Chauvierre C, Vauthier C, Labarre D, Couvreur P. Copolymere a structure sequencee compose d'un segment saccharidique lie a au moins un segment hydrophobe bioerodable, et particules correspondantes. French Patent 00 14900, 17.11.2000, PCT no. FR01/03619, 2000.
83. Chauvierre C, Labarre D, Couvreur P, Vauthier C. Radical polymerization of alkylcyanoacrylate to produce polysaccharide-coated nanoparticles. Proceedings of the 4th World Meeting on Pharmaceutics, Biopharmaceutics, Pharmaceutical Technology, ADRITELF, APGI, APV, Florence, 8-11 April, 2002.
84. Rouzes C, Gref R, Leonard M, Delgado A, Dellacherie E. Surface modification of polylactic nanopheres using hydrophobically modified dextrans as stabilizers in an o/w emulsion/evaporation technique. J. Biomed. Mater. Res 2000; 50:557-565.
85. Hamaide T, Pantiru M, Fessi H, Boullanger P. Ring opening polymerization of e-caprolactone with monosaccharides as transfert agents. A novel route to functionalized nanoparticles. Macromol. Rapid Comm 2001; 22:659.
86. Gref R, Ponchel G, Duchene D, Couvreur P. Materiaux a base de polymeres biodegradables et son procede de preparation. French Patent 00 06232, 16.03.2000, WO no. FRO 1/01496, 2000.
87. Fessi H, Devissaguet JP, Puisieux F. Procede de preparation de systemes colloidaux dispersibles d'une substance sous forme de nanoparticules. French Patent 2.608.988, 1986.
88. Marty JJ, Oppenheim RC, Speiser P. Nanoparticles a new colloidal drug delivery systems. Pharm. ActaHelv 1978; 53:17-23.
89. Stainmesse S. Etude galenique d'un nouveau procede d'obtention de vecteurs colloidaux submicroniques a partir d'une proteine ou d'un polymere synthetique, Ph.D. Thesis. France: Universite de Paris Sud, 1990.
90. Weber C, Coester C, Kreuter J, Langer K. Dessolvation process and surface characterization of protein nanoparticles. Int. J. Pharm 2000; 194:94-102.
91. Leong KW, Mao HQ, Truong-Le VL, Roy K, Walsh SM, August JT. DNA-polycation nanospheres as non-viral gene delivery vehicles. J. Control. Rel 1998; 53:183-193.
92. Truong-Le VL, Walsh SM, Schweibert E, Mao HQ, Guggino WB, August JT, Leong KW. Gene transfer by DNA-gelatin nanospheres. Arch. Biochem. Biophys 1999; 361:47-56.
93. Fessi H, Devissaguet JP, Puisieux F. Procede de preparation des systemes colloidaux dispersibles sous forme de nanocapsules. French Patent 86.18.444, 1986.
94. Legrand P, Barratt G, Mosqueira V, Fessi H, Devissaguet JP. Polymeric nanocapsules as drug delivery systems. A review. STP Pharma Sci 1999; 9:411-418.
95. Rajaonarivony M, Vauthier C, Couarraze G, Puisieux F, Couvreur P. Development of a new drug carrier made from alginate. J. Pharm. Sci 1993; 82:912-918.
96. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polym. Sci 1997; 63:125-132.
97. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Del. Rev 2001; 47:83-97.
98. Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery; preparation, properties and interactions with cells. Adv. Drug Del. Rev 2002; 54:135-147.
99. Mao HQ, Roy K, Walsh SM, August JT, Leong KW. Chitosan-DNA nanospheres for gene delivery. Proc. Intern. Symp. Control. Rel. Bioact. Mater 1996; 23:401-402.
100. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, August JT, Leong KW. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J. Control. Rel 2001; 70:399-421.
101. Kircheis R, Wightman L, Wagner E. Design and gene delivery activity of modified polyethyleneimines. Adv. Drug Del Rev 2001; 53:341-358.
102. Quintanar-Guerrero D, Alleman E, Doelker E, Fessi H. Preparation and characterization of nanocapsules from preformed polymers by a new process based on emulsification-diffusion technique. Pharm. Res 1998; 15:1056-1062.
103. Quintanar-Guerrero D, Alleman E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev. Ind. Pharm 1998; 24:1113-1128.
104. Quintanar-Guerrero D, Alleman E, Fessi H, Doelker E. Pseudolatex preparation using a novel emulsion-diffusion process involving direct displacement of partially water-miscible solvents by distillation. Int. J. Pharm 1999; 188:155-164.
105. Alleman E, Doelker E, Gurny R. Preparation of aqueous polymeric nanodispersions by a reversible salting-out process, influence of process parameters on particle size. Int. J. Pharm 1992; 87:247-253.
106. Alleman E, Doelker E, Gurny R. Drug loaded poly (lactic acid) nanoparticles produced by a reversible salting out process: purification of an injectable dosage form. Eur. J. Pharm, Biopharm 1993; 39: 13-18.
107. Gurny R, Peppas NA, Harrington DD, Banker GS. Development of biodegradable and injectable lattices for controlled release potent drugs. Drug Dev. Ind. Pharm 1981; 7:1-25.
108. Vanderhoff JW, El-Aasser MS, Ugelstad J. Polymer emulsification process. U.S. Patent 4.177.177, 1979.
109. Venier-Julienne MC, Benoit JP. Preparation, purification and morphology of polymeric nanoparticles as drug carrier. Pharm. Acta Helvctica 1996; 71:121-128.
110. Feng S, Huang S. G Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J. Control. Rei 2001; 71:53-69.
111. Zambaux MF, Bonneauz F, Gref R, Maincent P, Dellacherie E, Alonso MJ, Labrudc P, Vigncron C. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J. Control. Rei 1998; 50:31-40.
112. Blanco MD, Alonso MJ. Development and characterization of protein-loaded poly(lactide-co-gly­ colide) nanospheres. Eur. J. Pharm. Biopharm 1997; 43:287-294.
113. Berton M, Allemann E, Stein CA, Gurny R. Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex. Eur. J. Pharm. Sci 1999; 9:163-170.
114. Mosqueira VCR, Legrand P, Pinto-Alphandary H, Puisieux F, Barratt B. Poly(n.L-lactide) nanocap­ sules prepared by a solvent displacement process: Influence of the composition on physicochemical and structural properties. J. Pharm. Sci 2000; 89:614-626.
115. Gasper MM, Blanco D, Cruz ME, Alonso MJ. Formulation of L-asparaginase-loaded poly(lactic­ co-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release. J. Control. Rei 1998; 2:53-62.
116. Li YP, Pei YY, Zhang XY, Gu ZH, Zhou ZH, Yuan WE, Zhou JJ, Zhu KH, Gao XJ. PEGylated PLGA nanoparticles as protein carriers: synsthesis, preparation and biodistribution in rats. J. Control Rei 2001; 71:203-211.
117. Delie F, Berton M, Alleman E, Gurny R. Comparison of two metods of encapsulation of an oligonu­ cleotide into poly(D,L-lactic acid) particles. Int. J. Pharm 2001; 214:25-30.
118. Li YP, Pei YY, Zhou ZH, Zhang XY, Gu ZH, Ding J, Zhou JJ, Gao XJ. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-a carrier. J. Control Rei 2001; 71:287-296.
119. Sakuma S, Hayashi M, Akashi M. Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv. Drug Del. Rev 2001; 47:21-37.
120. Quintanar-Guerrero D, Alleman E, Fessi H, Doelker E. Application of the ion-pair concept to hydrophilic substances with special emphasis on peptides. Pharm. Res 1997; 14:119-127.
121. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez-Decampeneere D, Speiser P. Pharmacoki­ netics and distribution of a biodegradable drug-carrier. Int. J. Pharm 1983; 15:335-345.
122. Lenaerts V, Nagelkerke JF, Van Berkel TJ, Couvreur P, Grislain L, Roland M, Speiser P. In vivo uptake of polyisobutyl cyanoacrylate nanoparticles by rat liver Kupffer, endothelial, and parenchy­ mal cells. J. Pharm. Sci 1984; 73:980-982.
123. Lenaerts V, Couvreur P, Christiaens-Leyh D, Joiris E, Roland M, Rollman B, Speiser P. Degradation of poly(isobutyl cyanoacrylate) nanoparticles. Biomaterials 1984; 5:65-68.
124. Chavany C, Ledoan T, Couvreur P, Puisieux F, Helene C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm. Res 1992; 9:441-449.
125. Pinto-Alphandary H, Andremont A, Couvreur P. Targeting delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrob. Agents 2000; 13:155-168.
126. Fattal E, Youssef M, Couvreur P, Andremont A. Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob. Agents Chemother 1989; 33:1540-1543.
127. Youssef M, Fattal E, Alonso MJ, Roblot-Treupel L, Sauzieres J, Tancrede C, Omnes A, Couvreur P, Andremont A. Effectiveness of nanoparticle-bound ampicillin in the treatment of Listeria monocy­ togenes infection in athymic nude mice. Antimicrob. Agents Chemother 1988; 32:1204-1207.
128. Forestier F, Gerrier P, Chaumard C, Quero AM, Couvreur P, Labarre C. Effect of nanoparticle­ bound ampicillin on the survival of Listeria monocytogenes in mouse peritoneal macrophages. J. Antimicrob. Chemother 1992; 30:173-179.
129. Balland O, Pinto-Alphandary H, Pecquet S, Andremont A, Couvreur P. The uptake of ampicillin­ loaded nanoparticles by murine macrophages infected with Salmonella typhimurium. J. Antimicrob. Chemother 1994; 33:509-522.
130. Pinto-Alphandary H, Balland O, Laurent M, Andremont A, Puisieux F, Couvreur P. Intracellular visualization of ampicillin-loaded nanoparticles in peritoneal macrophages infected in vitro with Salmonella typhimurium. Phann. Res 1994; 11:38-46.
131. Buchmeier NA, Heffron F. Inhibition of macrophage phagosome-lysosome fusion by Salmonella typhimurium. Infect. lmmun 199 I; 59:2232-2238.
132. Page-Clisson ME, Pinto-Alphandary H, Chachaty E, Couvreur P, Andremont A. Drug targeting by polyalkylcyanoacrylate nanoparticles is not efficient against persistent Salmonella. Pharm. Res 1998: 15:544-549.
133. Zhang Q, Liao G, Wei D, Nagai T. Increase in gentamicin uptake by cultured mouse peritoneal macrophages and rat hepatocytes by its bioding to polybutylcyanoacrylate nanoparticles. Int. J. Pharm 1998; 164:21-27.
134. Gaspar R, Opperdoes FR, Preat V, Roland M. Drug targeting with polyalkylcyanoacrylate nanopar­ ticles-in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania dono­ vani. Ann Tropical Med Parasitology 1992; 86:41-49.
135. Gaspar R, Preat V, Opperdoes FR, Roland M. Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular Leishmania dono\'Clni associated with hy­ drogen peroxide production. Pharm. Res 1992; 9:782-787.
136. Fouarge M, Dewulf M, Couvreur P, Roland M, Vranckx H. Development of dehydroemetine nano­ particles for the treatment of visceral leishmaniasis. J. Microencapsulation 1989; 6:29-34.
137. Verdun C, Brasseur F, Vranckx H, Couvreur P, Roland M. Tissue distribution of Doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother. Pharmacol 1990; 26: 13-18.
138. Chiannilkulchai N, Ammoury N, Caillou B, Devissaguet JP, Couvreur P. Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metas­ tasis-bearing mice. Cancer Chemother. Pharmacol 1990; 26:122-126.
139. Brasseur F, Verdun C, Couvreur P, Deckers C, Roland M. Evaluation experimentale de l'efficacite therapeutique de la doxorubicine associee associee aux nanoparticules de polyalkylcyanoacrylate. Proceedings of the 4th International Conference on Pharmaceutical Technology. 1986. APGI, Paris, 1986.
140. Chiannilkulchai N, Driouich Z, Benoit JP, Parodi AL, Couvreur P. Doxorubicin-loaded nanopar­ ticles: increased efficiency in murine hepatic metastases. Sel. Cancer Ther 1989; 5:1-11.
141. Daemen T, Hofstede G, Ten Kate MT, Bakker-Woudenberg IA, Scherphof GL. Liposomal doxoruhi­ cin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int. J. Cancer 1995; 61:716-721.
142. Fernandez-Urrusuno R, Fattal E, Porquet D, Feger J, Couvreur P. Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles. Toxicol. Appl. Pharmacol 1995; 130: 272-279.
143. Fernandez-Urrusuno R, Fattal E, Rodrigues JM, Feger J, Bedossa P, Couvreur P. Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J. Biomed. Mater. Res 1996; 31:401-408.
144. Gibaud S, Andreux JP, Weingarten C, Renard M, Couvreur P. Increased hone marrow toxicity of doxorubicin bound to nanoparticles. Eur. J. Cancer 1994; 6:820-826.
145. Gibaud S, Rousseau C, Weingarten C, Favier R, Douay L, and P. Polyalkylcyanoacrylate nanopar­ ticles as carriers for granulocyte-colony stimulating factor (G-CSF). J. Control. Rei 1998; 52: 131-139.
146. Demoy M, Gibaud S, Andreux JP, Weingarten C, Gouritin B, Couvreur P. Splenic trapping of nanoparticles: complementary approaches for in situ studies. Pharm. Res 1997; 14:463-468.
147. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug­ resistant cell lines by monoclonal antibodies. Nature 1985; 316:820-823.
148. Treupel L, Poupon MF, Couvreur P, Puisieux F. Vectorization of doxorubicin in nanospheres and reversion of pleiotropic resistance of tumor cells (translation). C. R. Acad. Sci. III 1991; 313: 171-174.
149. Cuvier C, Roblot-Treupcl L, Millot JM, Lizard G, Chevillard S, Manfait M, Couvreur P, Poupon MF. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol 1992; 44:509-517.
150. Bennis S, Chapcy C, Couvreur P, Robert J. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. Eur. J. Cancer 1994; 1:89-93.
151. Nemati F, Dubemet C, Colin de Verdiere A, Poupon MF, Acar L, Puisicux F, Couvreur P. Some parameters influencing cytotoxicity of free doxorubicin loaded nanoparticles in sensitive and multid­ rug resistant leucemic murine cells: incubation time, number of particles per cell. Int. J. Pharm 1994; 102:55-62.
152. Colin de Verdiere A, Dubernet C, Nemati F, Poupon MF, Puisieux F, Couvreur P. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother. Pharmacol 1994; 33:504-508.
153. Colin de Verdiere A, Dubemet C, Nemati F, Soma E, Appel M, Ferte J, Bernard S, Puisieux F, Couvreur P. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br. J. Cancer 1997; 76:198-205.
154. Pepin X, Attali L, Domrault C, Gallet S, Metreau JM, Reault Y, Cardot PJ, lmalalen M, Dubernet C, Soma E, Couvreur P. On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. J. Chromatogr. B: Bio­ med. Sci. Appl 1997; 702:181-191.
155. Soma CE, Dubernet C, Barratt G, Nemati F, Appel M, Benita S, Couvreur P. Ability of doxorubicin­ loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macro­ phages. Pharm. Res 1999; 16:1710-1716.
156. Soma CE, Dubernet C, Barratt G, Benita S, Couvreur P. Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J. Control. Rei 2000; 68:283-289.
157. Morin C, Barratt G, Fessi H, Devissaguet JP, Puisieux F. Improved intracellular delivery of a muramyl dipeptide analog by means ofnanocapsules. Int. J. Immunopharmacol 1994; 16:451-456.
158. Seyler I, Appel M, Devissaguet JP, Legrand P, Barratt G. Relationship between NO-synthase activity and TNF-alpha secretion in mouse macrophage lines stimulated by a muramyl peptide entrapped in nanocapsules. Int. J. lmmunopharmacol 1996; 18:385-392.
159. Seyler I, Appel M, Devissaguet JP, Legrand P, Barratt G. Macrophage activation by a lipophilic derivative of Muramyldipeptide. J. Nanoparticle Res 1999; 1:91-97.
160. Barratt G, Puisieux F, Yu WP, Foucher C, Fessi H, Devissaguet JP. Anti-metastatic activity of MDP-L-alanyl-cholesterol incorporated into various types of nanocapsules. Int. J. Immunopharmacol 1994; 16:457-461.
161. Chavany C, Saison-Behmoaras T, Doan T, Puisieux F, Couvreur P, Helene C. Adsorption of oligonu­ cleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res 1994; 11:1370-1378.
162. Fattal E, Vauthier C, Aynie I, Nakada Y, Lambert G, Malvy C, Couvreur P. Biodegradable polyalkyl­ cyanoacrylate nanoparticles for the delivery of oligonucleotides. J. Control Rei 1998; 53:137-143.
163. Emile C, Bazile D, Herman F, Helene C, Veillard M. Me.PEG-PLA50 nanoparticles by compexation with strucutred oligopcptides. Drug Delivery 1996; 3:187-195.
164. Nakada Y, Fattal E, Foulquier M, Couvreur P. Pharmacokinetics and biodistribution of oligonucleo­ tide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Pharm. Res 1996; 13:38-43.
165. Schwab G, Chavany C, Duroux I, Goubin G, Lebeau J, Helene C, Saison-Behmoaras T. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha­ ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. USA 1994; 91: 10460-10464.
166. Lambert G, Fattal E, Brehier A, Feger J, Couvreur P. Effect of polyisobutylcyanoacrylate nanopar­ ticles and lipofectin loaded with oligonucleotides on cell viability and PKC alpha neosynthesis in HepG2 cells. Biochimie 1998; 80:969-976.
167. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P. Polyisobutylcyanoacrylate nanocap­ sules containing an aqueous core for the delivery of oligonucleotides. Int. J. Pharm 2001; 214: 13-16.
168. Lambert G, Bertrand JR, Fattal E, Subra F, Pinto-Alphandary H, Malvy C, Auclair C, Couvreur P. EWS fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun 2000; 279:401-406.
169. Tanaka K, lwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli I antiscnse oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J. Clin. Invest 1997; 99:239-247.
170. Stein CA. Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Biotechnol 1996; 14:47-149.
171. Aynie I, Vauthier C, Chacun H, Fattal E, Couvreur P. Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 1999; 9:301-312.
172. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Dmg Del. Rev 2001; 47:65-81.
173. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995; 674:171-174.
174. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Phann. Res 1997; 14:325-328.
175. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate SO-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencapsulation 1998; 15:67-74.
176. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Phann. Biopharm 2000; 49:103-109.
177. Sopala M, Schweizer S, Schafer N, Nurnberg E, Kreuter J, Seiller E, Danysz W. Neuroprotective activity of a nanoparticulate formulation of the glycineB site antagonist MRZ 2/576 in transient focal ischaemia in rats. Arzneimittelforschung 2002; 52:168-174.
178. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Phann. Res 1999; 16: 1564-1569.
179. Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B, Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoac­ rylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett 2002; 126: 131-141.
180. Ramge P, Unger RE, Oltrogge JB, Zenker D, Begley D, Kreuter J, Briesen H. Polysorbate 80 coating enhances uptake of polybutylcyanoacrylate (PECA) nanoparticles by human and bovine primary brain capillary endothelial cells. Eur. J. Neurosci 2000; 12:1931-1940.
181. Alyaudtin RN, Reichel A, Lobenberg R., Ramge P, Kreuter J, Begley DJ. Interaction of poly(butylcy­anoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J. Drug Target 2001; 9:209-221.
182. Araujo L, Lobenberg R, Kreuter J. Influence of the surfactant concentration on the body distribution of nanoparticles. J. Drug Target 1999; 6:373-385.
183. Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Phann. Res 1999; 16:1836-1842.
184. Calvo P, Gouritin B, Chacun H, Desmaele D, D' Angelo J, Noel JP, Georgin D, Fattal E, Andreux JP, Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res 2001; 18:1157-1166.
185. Calvo P, Gouritin B, Villarroya H, Eclancher F, Giannavola C, Klein C, Andreux JP, Couvreur P. Quantification and localization of PEGylated polycyanoacrylate nanoparticlcs in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur. J. Neurosci 2002; 15:1317-1326.
186. Calvo P, Gouritin B, Brigger I, Lasmezas C, Deslys J, Williams A, Andreux JP, Dormont D, Couvrcur P. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J. Neurosci. Methods 2001; 111:151-155.
187. Gautier JC, Grangier JL, Barbier A, Dupont P, Dussosoy D, Pastor G, Couvreur P. Biodegradable nanoparticles for subcutaneous adminstration of growth hormone releasing factor (hGRF). J. Control. Rei 1992; 3:205-210.
188. Kreuter J, Speiser PP. In vitro studies of poly(methyl methacrylate) adjuvants. J. Pharm. Sci 1976; 65:1624-1627.
189. Kreuter J. Possibilities of using nanoparticles as carriers for drugs and vaccines. J. Microencapsulation 1988; 5:115-127.
190. Kreuter J, Liehl E. Long-term studies of microencapsulated and adsorbed influenza vaccine nanoparticles. J. Pharm. Sci 1981; 70:367-371.
191. Kreuter J, Haenzel I. Mode of action of immunological adjuvants: some physicochemical factors influencing the effectivity of polyacrylic adjuvants. Infect. Immun 1978; 19:667-675.
192. Kreuter J, Berg U, Lichl E, Soliva M, Speiser PP. Influence of the particle size on the adjuvant effect of particulate polymeric adjuvants. Vaccine 1986; 4:125-129.
193. Kreuter J, Lichl E, Berg U, Soliva M, Speiser PP. Influence of hydrophobicity on the adjuvant effect of particulate polymeric adjuvants. Vaccine 1988; 6:253-256.
194. Jani P, Halbert GW, Langridge J, Florence AT. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol 1989; 41:809-812.
195. Le Fevre HE, Joel DD, Shidlousky G. Retention of ingested latex particles in Peyers patches of gerin-free and conventional mice. Soc. Exp. Biol. Med 1985; 179:522-528.
196. Damge C, Michel C, Aprahamian M, Couvreur P, Devissaguet JP. Nanocapsules as carriers for oral peptide delivery. J. Control. Rei 1990; 13:233-239.
197. Aprahamian M, Michel C, Humbert W, Devissaguet JP, Damge C. Transmucosal passage ofpolyal­ kylcyanoacrylate nanocapsulcs as a new drug carrier in the small intestine. Biol. Cell 1987; 61: 69-76.
198. McClean S, Prosser E, Meehan E, O'Malley D, Clarke N, Ramtoola Z, Brayden D. Binding and uptake of biodegradable poly-oL-lactide micro and nanoparticles in intestinal epithelia. Eur. J. Pharm. Sci 1998; 6: 153-163.
199. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable micropar­ ticles: effect of particle size. Pharm. Res 1996; 13:1838-1845.
200. Lowe PJ, Temple CS. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. J. Pharm. Pharmacol 1994; 46:547-552.
201. Michel C, Aprahamian M, Defontaine L, Couvreur P, Damge C. The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J. Pharm. Pharmacol 1990; 43:1-5.
202. Aboubakar M, Couvreur P, Pinto-Alphandary H, Gouritin B, Lacour B, Farinotti R, Puisieux F, Vauthier C. Insulin-loaded nanocapsules for oral administration: in vitro and in viva investigation. Drug Dev. Res 2000; 49: 109-117.
203. Damgc C, Vranckx H, Balschmidt P, Couvreur P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci 1997; 86:1403-1409.
204. Watnasirichaikul S, Rades T, Tucker IG, Davies NM. In-vitro release and oral bioavailability in diabetic rats of insulin using nanocapsules dispersed in biocompatible microemulsion. J. Pharm. Pharmacol 2002; 54:473-480.
205. Torres-Lugo M, Peppas NA. Transmucosal delivery systems for calcitonin: a review. Biomaterials 2000; 21:1191-1196.
206. O' Hagan OT, Palin K, Davis SS. Poly(butyl-2-cyanoacrylate) particles as adjuvant for oral immunization. Vaccine 1989; 7:213-216.
207. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev 2001; 47:39-54.
208. Ponchel G, Touchard F, Duchene D, Peppas NA. Bioadhesive analysis of the controlled-release systems. Ill. Fracture and interpenetration analysis in poly(acrylic acid) containing systems. J. Control. Rei 1987; 5:129-141.
209. Ponchel G, Irache J. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev 1998; 34:191-219.
210. Pimienta C, Chouinard F, Labib A, Lenaerts V. Effect of various poloxamer coatings on in vitro adhesion of isohexylcyanoacrylate nanospheres to rat ileal segments under liquid flow. Int. J. Pharm 1992; 80:1-8.
211. Lenaerts V, Couvreur P, Grislain L, Maincent P. Nanoparticles as a gastrointestinal drug delivery system. In: Lenaerts V, Gurny R, eds. Bioadhesive Drug Delivery Systems. Boca Raton. FL: CRC Press, 1990:94-104.
212. Kreuter J, Muller V, Munz K. Quantitative and microautoradiographic study on mouse intestinal distribution of polycyanoacrylate nanoparticles. Int. J. Pharm 1989; 55:39-45.
213. Maincent P, Le Verge R, Sado P, Couvreur P, Devissaguet JP. Disposition kinetics and oral hioavail­ ability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles. J.Pharm.Sci 1986; 75:955-958.
214. Damge C, Aprahamian M, Balboni G, Hoeltzel A, Andrieu V, Devissaguet JP. Polyalkylcyanoacry­ late nanocapsules increase the intestinal absorption of a lipophilic drug. Int. J. Pharm 1987; 36: 121-125.
215. Hubert B, Atkinson J, Guerret M, Hoffman M, Devissaguet JP, Maincent P. The preparation and acute antihypertensive effects of a nanocapsular form of darodipinc, a dihydropyridine calcium entry blocker. Pharm. Res 1991; 8:734-738.
216. Ammoury N, Fessi H, Devissaguet JP, Dubrasquet M, Benita S. Jejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly(D.L-lactide) and poly(isobu­ tyl-cyanoacrylate) nanocapsules in rats. Pharm. Res 1991; 8:101-105.
217. Boudad H, Legrand P, Coconnier MH, Appel M, Duchene D, Ponchel G. Absorption of saquinavir from combined hydroxypropyl 13 cyclodextrin and poly(alkylcyanoacrylate) nanoparticles through CACO-2 cells monolayers. Proceedings of the 4th World Meeting on Pharmaceutics, Biopharmaceu­ tics, and Pharmaceutical Technology, ADRITELF, APGI, APV, Florence, 8-11 April 2002, 2002.
218. Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P. Poly(c-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm. Res 1993; 10:386-390.
219. Marchal-Heussler L, Fessi H, Devissaguet JP, Hoffman M, Maincent P. Colloidal drug delivery systems for the eye. A comparison ofthe efficacy of three different polymers: polyisobutylcyanoacry­ late, poly(lactic-co-glycolic acid), poly(c-caprolactone). S.T.P. Pharma 1992; 2:98-104.
220. Losa C, Marchal-Heussler L, Orallo F, Vila Jato JL, Alonso MJ. Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm. Res 1993; 10:80-87.
221. Calvo P, Thomas C, Alonso MJ, Vila Jato JL, Robinson JR. Study of the mechanism of interaction of poly(c-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy. Int. J. Pharm 1994; 103:283-291.
222. Zimmer A, Kreuter J, Robinson JR. Studies on the transport pathway of PBCA nanoparticles in ocular tissues. J. Microencapsulation 1991; 8:497-504.
223. Calvo P, Alonso MJ, Vila-Jato JL, Robinson JR. Improved ocular hioavailahility of indomethacin by novel ocular drug carriers. J. Pharm. Pharmacol 1996; 48:1147-1152.
224. Calvo P, Vila-Jato JL, Alonso MJ. Effect of lysozyme on the stability of polyester nanocapsules and nanoparticles: stabilization approaches. Biomaterials 1997; 18:1305-1310.
225. Calvo P, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int. J. Pharm 1997; 153:41-50.
226. Calvo P, Sanchez A, Martinez J, Lopez MI, Calonge M, Pastor JC, Alonso MJ. Polyester nanocap­ sules as new topical ocular delivery systems for cyclosporin A. Phann. Res[. Pharm. Res;] 1996; 13(9):1423.
227. Juberias JR, Calonge M, Gomez S, Lopez MI, Calvo P, Herreras JM, Alonso MJ. Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat. Curr. Eye Res 1998; 17: 39-46.
228. De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm 2001; 224:159-168.
229. Le Bourlais CA, Chevanne F, Turlin B, Acar L, Zia H, Sado PA, Needham TE, Leverge R. Effect of cyclosporin A formulations on bovine corneal absorption: ex-vivo study. J. Microencapsulation 1997; 14:457-467.
230. Desai SD, Blanchard J. Pluronic® Fl27-based ocular delivery systems containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine. Drug Delivery. J Delivery Targeting Thera­ peutic Agents 2000; 7:201-207.
231. Fresta M, Fontana G, Bucolo C, Cavallaro G, Giammona G, Puglisi G. Ocular tolerability and in vivo bioacailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanospheres­encapsulated acyclovir. J. Pharm. Sci 2001; 9:288-297.